Vitamin D Deficiency Treatment Outcomes on Inflammation, Endothelial Function and Ventricular Retrieval After Non ST-Segment Elevation Myocardial Infarction: A Randomized Placebo Controlled Clinical Trial (NAVID Study)
试验速览
- 阶段
- 2 期
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- endothelial function(1) change from baseline
研究概览
简要总结
The leading cause of death in the world is due to cardiovascular events, which originate from coronary artery stenosis therefore it affects myocardial blood flow and finally may cause infarction. Atherosclerosis is the most debatable hypothesis in coronary stenosis. Scientists think body inflammation is one of the main etiologies. There are many factors affect this inflammatory process, which Vitamin D is one of them. Vitamin D deficiency has been linked to various inflammatory diseases. However, the mechanism by which vitamin D reduces inflammation remains poorly understood. Vitamin D deficiency is pandemic around the world with 30-50% prevalence in adult population and several evidences advocated its association with immune-based disease. Additionally, there are some study suggesting patients who suffered from myocardial infarction have lower serum vitamin D level. It has been revealed Vitamin D deficiency has numerous major drawbacks on cardiovascular system. Its deficiency benefits atherosclerosis progression and may cause endothelial inflammation and dysfunction in coronary artery. There is not any evidences study vitamin D deficiency treatment on non ST-Segment Elevation Myocardial Infarction nor there is any study demonstrating its effect on cardiovascular health through Holick's protocol. Furthermore endothelial function, cardiac work retrieval and inflammation after 8 weeks has not been studied with this protocol yet.
According to current data, the investigators assume by treating this vital and worldwide deficit in our body, doctors can help decrease inflammation, decelerate the atherosclerosis progression and enhance ventricular function after infarction.
Besides all of the recognized risk factors, vitamin D deficiency should be considered a very important and mischievous cardiovascular alarm for the body, which should be treated and maintained through the whole life due to lack of sufficient sunlight exposure and nutrition intake.
In preventive medicine domain, the investigators anticipate by maintaining a high level of this vitamin in the body, cardiovascular events decrease and its burden on society will decline to much extend leading to a higher quality of life and health worldwide.
详细描述
The leading cause of death in the world is due to cardiovascular events, which originate from coronary artery stenosis therefore it affects myocardial blood flow and finally may cause infarction. ST-Segment elevation is an indicator of infarction (STEMI) in electrocardiography (ECG) besides cardiac enzymes like troponin; however, there is another type of infarction without elevation, which called non ST-Segment Elevation myocardial infarction (NSTEMI).
The most established method of treating this condition is percutaneous coronary intervention (PCI) and balloon angiography although in some cases coronary artery bypass grafting surgery is more beneficial. Atherosclerosis is the most debatable hypothesis in coronary stenosis. Scientists think body inflammation is one of the main etiologies. There are many factors affect this inflammatory process, which Vitamin D is one of them. Vitamin D deficiency has been linked to various inflammatory diseases. However, the mechanism by which vitamin D reduces inflammation remains poorly understood. Vitamin D Inhibits Monocyte/Macrophages Pro-inflammatory Cytokine Production by Targeting mitogen-activated protein kinase (MAPK) Phosphatase-1 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway therefore decrease production of IL-6 and tumor necrosis factor-alpha (TNFα) and increasing interleukin (IL) 10 and transforming growth factor beta (TGFβ) from human monocytes. Chronic inflammatory diseases that are vitamin D deficient (20 ng/ml) may benefit from oral supplementation of vitamin D to get their serum vitamin D level>30 ng/ml.
Galectin-3 is emerging fibrotic biomarkers that is thought to be causally involved in the development of heart failure. Galectin-3 is a beta-galactoside binding lectin that is produced by macrophages during myocardial stress and activates fibroblasts. Besides its roles in inflammation and in cellular adhesion, galectin-3 plays an important role in cardiac fibrosis. Furthermore, galectin-3 has an established role as a modulator in tumor progression. Galectin-3 is released in the circulation, and can be measured reliably and has been shown to independently predict outcomes in heart failure patients and in the general population. However, galectin-3 is not cardiac specific, but is expressed in several fibrotic and inflammatory diseases.
Vitamin D is one of the fat-soluble micronutrients, which sunlight is the principle key to make this vitamin in our body. Vitamin D deficiency is pandemic around the world with 30-50% prevalence in adult population and several evidences advocated its association with immune-based disease like asthma, multiple sclerosis (MS), Type 2 diabetes and many cancers. Additionally, there are some study suggesting patients who suffered from myocardial infarction have lower serum vitamin D level. It has been revealed Vitamin D deficiency has numerous major drawbacks on cardiovascular system. Its deficiency benefits atherosclerosis progression and may cause endothelial inflammation and dysfunction in coronary artery. Endothelial malfunction with lipid sedimentation beneath the intima layer attract leukocytes and make foam cells. Therefore it leads to produce active agents and make smooth muscle cells to proliferate and lead the lumen to be narrower, which consequently decrease oxygenated blood flow and causes ischemia and infarction. Monocyte chemoattractant protein 1 (MCP-1) and n-terminal fragment of pro-brain natriuretic peptide (NT-pro-BNP) are two newly discovered molecules associated independently with coronary calcification level. MCP-1 has a role in representing the relationship between acute myocardial infarction and inflammation.
Renin-Angiotensin-Aldosterone system has a principle role in blood pressure maintenance. It has been shown this vitamin can regulate this system too.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 40 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •30-65 years old patients
- •Hypovitaminosis D (serum 25(OH) Vitamin D< 20 ng/ml)
- •Written and informed consent to participate in this project
- •Non ST-Segment Elevation Myocardial Infarction: any patients with chest pain or any discomfort and suspected MI who referred to our Heart Center Emergency Room without any ST-Segment Elevation (according to J-point) in 12-lead ECG (according to American Heart Association (AHA) guidelines) plus increasing level of serum cardiac Troponin I
排除标准
- •Normal Vitamin D level
- •Body mass index (BMI)>30 kg/m2
- •Do not tend to attend in this study
- •Any life-threatening medical condition
- •Hyperparathyroidism (parathyroid hormone (PTH)>upper normal limit according to lab reference range)
- •Liver failure (any positive past medical history or Aspartate and Alanine aminotransferase (AST and ALT) 2 times more than normal upper limit)
- •Renal Failure (any positive past medical history or Glomerular filtration rate <60 ml/min/1.73 m2 estimated with MDRD formula of Qx calculate application)
- •Any prior history of diagnosed cancer, rheumatologic and immunologic disorders
研究组 & 干预措施
active drug receiving group
the drug is vitamin D3 50000 UNT oral capsule prescribing under Holick's protocol, which is every week for 8 weeks then every month for long life
干预措施: Vitamin D3 50000 UNT Oral Capsule (Drug)
placebo receiving group
the same as active comparator unless the drug is the identical placebo oral capsule
干预措施: Placebo oral capsule (Drug)
结局指标
主要结局
endothelial function(1) change from baseline
时间窗: change from baseline at 8th weeks after infarction
E-Selectin of blood
endothelial function(2) change from baseline
时间窗: change from baseline at 8th weeks after infarction
fibroblast growth factor 21 of blood
endothelial function(3) change from baseline
时间窗: change from baseline at 8th weeks after infarction
fibroblast growth factor 23 of blood
endothelial function(6) change from baseline
时间窗: change from baseline at 8th weeks after infarction
with flow mediated dilation (FMD)
endothelial function(4) change from baseline
时间窗: change from baseline at 8th weeks after infarction
vascular cell adhesion molecule 1 of blood
endothelial function(5) change from baseline
时间窗: change from baseline at 8th weeks after infarction
inter-cellular cell adhesion molecule 1 of blood
次要结局
- inflammation state(1) changes from baseline(change from baseline at 8th weeks after infarction)
- inflammation state(2) changes from baseline(change from baseline at 8th weeks after infarction)
- ventricular function(5) changes from baseline(change from baseline at 8th weeks after infarction)
- ventricular function(1) changes from baseline(change from baseline at 8th weeks after infarction)
- inflammation state(3) changes from baseline(change from baseline at 8th weeks after infarction)
- inflammation state(4) changes from baseline(change from baseline at 8th weeks after infarction)
- ventricular function(3) changes from baseline(change from baseline at 8th weeks after infarction)
- ventricular function(4) changes from baseline(change from baseline at 8th weeks after infarction)
- inflammation state(5) changes from baseline(change from baseline at 8th weeks after infarction)
- ventricular function(2) changes from baseline(change from baseline at 8th weeks after infarction)
研究者
Masoumeh Sadeghi
Dr. Masoumeh Sadeghi
Isfahan University of Medical Sciences
